Your browser is old and is not supported. Upgrade for better security.

Invest in Vironix Health Inc.

AI-Enabled Early Detection and Remote Monitoring of Lung and Heart Disease

Highlights

1
❤️ Vironix Outperforms Standard-of-Care in Detecting/Triaging Heart Failure, COPD & Asthma Flare-ups
2
💸 $150M Potential ARR from Current LOIs (not guaranteed)
3
💪 APIs Raise Wellness, Scale Globally, & Grow Revenue for Caregivers
4
💰 $450K Raised in Pre-Seed/Seed capital to date; $350K Invested Into R&D
5
🤝 World Class R&D Collaboration w/ Oxford University
6
📜 Patent Pending on Early Detection Technology (USPTO: 63/316,078)
7
🎓 2021 Mass Challenge Accelerator Alum & ✊ Certified Minority Controlled Enterprise
8
📖 Peer-Reviewed Publications and Invited Talks w/ Duke, Kaiser-Permanente, & Oxford.

Our Team

Heart and lung disease deterioration events are leading causes of global death/morbidity with a price tag of $100s of billions in hospitalization, treatment, lost productivity, and mental illness. It is well known that early intervention at home constitutes the best opportunity for real global prevention and increased quality-of-life.

Why Vironix?

VIRONIX’s AI Technology can potentially save lives by early detection and intervention on Heart Failure, COPD, Asthma, and Acute Respiratory illnesses. 

The Problem:

Cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year and amounting to one death every 56 seconds. Either you or someone you know has been impacted by heart disease. 

Chronic lung disease (COPD & Asthma) is the third leading cause of death around the globe with a price tag of a whopping $130B in direct spending! People diagnosed with or at risk of Heart Failure, COPD, Asthma, & Acute Respiratory Illness face constant risk of death, hospitalization, massive healthcare expenditures, and persistent anxiety driven by singular health deterioration episodes (exacerbations & infections) that, if detected and managed early, are readily addressed at home with diet, medication, and rest.

🧠 The Solution: VIRONIX AI

Vironix makes AI-enabled therapeutic monitoring software that helps people to catch and intervene early on dangerous health deterioration episodes.

** Note that Vironix's AI products evolve and improve every day. The above figures include peer-reviewed algorithm performance and clinical efficacy data spanning 6 years of our research. Vironix's current AI capabilities incorporate methods from the above studies, but our products implement a broader and more advanced set of prediction models and user workflows.**

💎 VALUE PROPOSITION: How we are better

Our key differentiation is that we simultaneously:

1) outperform standard-of-care in identifying and triaging flare-ups

2) seamlessly integrate into existing physician/patient software/hardware

3) reduce patient symptom severity and increase quality-of-life

4) provide AI-personalized and gamified software for maximum patient adoption

5) help caregivers generate up to $300 per patient per month in health insurance reimbursement through established remote monitoring and chronic care CPT codes.

Consequently, patient safety and health go up, provider revenue goes up, and global mortality/morbidity goes way down.

    👋🏻 Clients & Collaborators

    VIRONIX requires no upfront investment from patients or physicians ....we don’t get paid until our customers get paid!  

    For more context check out our documentary feature on Viewpoint w/ actor Dennis Quaid:

    Check out our interview with Pulmonologist, Dr. Nicholas Wysham to hear his thoughts on Vironix AI 


    🦸🏻‍♂️ TEAM - Multi-disciplinary, with proven expertise

    Our team comprises the top physicians, technologists, healthcare entrepreneurs, and data scientists in the world with numerous peer-reviewed publications to our name and R&D collaborations with Oxford, Duke, and Kaiser Permanente to name a few.

    🦄 BUSINESS MODEL – And why this is a Smart Investment Opportunity

    To date, Vironix has a paying beta customer, a completed POC with an $8B ARR system integration partner, strong clinical efficacy data, letters of intent for patient monitoring, and employer wellness contracts representing ~$1.8 billion revenue opportunity. 

    🥇COMPETITION – We are doing it better than anyone else

    Forward-looking projections, cannot be guaranteed

    Vironix is raising capital to fund pilot completion, product development, and go-to-market strategy to aggressively bring these invaluable healthcare products to patients, providers, and global institutions.

    🚀 Top 5 Reasons to Invest in VIRONIX

    1) Products outperform standard-of-care in addressing the world's leading causes of preventable death, hospitalization, and morbidity.

    2) A $400B market opportunity, $150B addressable market, and 38% annual growth rate (and climbing).

    3) Team includes seasoned founders/executives with successful exits and the world's best minds in AI, clinical science, and scalable technology.

    4) Patent pending, clinically tested technology scales globally with high adoption.

    5) Existing pilot partner traction suggests a very attractive ROI with a clear exit path.

      Overview